- Clinical Trials
- April 2024
- 60 Pages
Global
From €1922EUR$2,000USD£1,652GBP
- Report
- January 2022
- 200 Pages
Global
From €7206EUR$7,500USD£6,197GBP
- Report
- January 2022
- 60 Pages
Global
From €3795EUR$3,950USD£3,264GBP
- Drug Pipelines
- January 2019
- 60 Pages
Global
From €1922EUR$2,000USD£1,652GBP
- Report
- July 2022
Global
From €4324EUR$4,500USD£3,718GBP
- Drug Pipelines
- November 2020
- 108 Pages
Global
From €1922EUR$2,000USD£1,652GBP
- Report
- February 2024
- 96 Pages
Global
From €3500EUR$3,902USD£3,115GBP
- Report
- September 2022
- 78 Pages
Global
From €1922EUR$2,000USD£1,652GBP
- Report
- May 2022
- 84 Pages
Global
From €1922EUR$2,000USD£1,652GBP
Enterococcus Faecium is a type of bacteria that can cause serious infections in humans. It is a common cause of hospital-acquired infections, such as urinary tract infections, endocarditis, and bacteremia. Treatment of Enterococcus Faecium infections typically involves antibiotics, such as vancomycin, linezolid, and daptomycin. The market for drugs to treat Enterococcus Faecium infections is highly competitive, with many companies developing and marketing drugs to treat this type of infection. Companies are also researching new drugs to treat Enterococcus Faecium infections, as well as developing combination therapies to improve the effectiveness of existing treatments.
Some of the companies in the Enterococcus Faecium market include Merck & Co., Pfizer, AstraZeneca, GlaxoSmithKline, Novartis, Sanofi, and Johnson & Johnson. Show Less Read more
